Live price temporarily unavailable.
Alzamend Neuro (ALZN) is a Health Care company. Latest news and coverage below.
| FY2020Apr 2020 | FY2021Apr 2021 | FY2022Apr 2022 | FY2023Apr 2023 | FY2024Apr 2024 | FY2025Apr 2025 | FY2026Apr 2026 | |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Operating income | −$4.42M | −$4.95M | −$12.3M | −$14.9M | −$9.94M | −$4.50M | −$8.77M |
| Net income | −$4.41M | −$5.05M | −$12.4M | −$14.9M | −$9.95M | −$4.51M | −$8.77M |
| EPS (diluted) | −$1350.00 | −$1575.00 | −$21.00 | −$228.90 | −$132.33 | −$11.32 | −$2.63 |
| Balance sheet | |||||||
| Cash and equivalents | $90.3K | $1.93M | $14.1M | $5.14M | $376.0K | $3.95M | $710.7K |
| Total assets | $1.81M | $2.91M | $14.5M | $5.92M | $631.6K | $4.60M | $2.08M |
| Total liabilities | $992.3K | $899.6K | $1.16M | $2.87M | $3.23M | $634.8K | $1.35M |
| Shareholders' equity | $821.7K | $2.01M | $13.4M | $3.05M | −$2.59M | $3.97M | $733.2K |
| Cash flow | |||||||
| Operating cash flow | −$2.35M | −$2.71M | −$6.61M | −$8.92M | −$8.27M | −$6.57M | −$8.07M |
| Q2 FY25Oct 2024 | Q3 FY25Jan 2025 | Q4 FY25†Apr 2025 | Q1 FY26Jul 2025 | Q2 FY26Oct 2025 | Q3 FY26Jan 2026 | Q4 FY26†Apr 2026 | Q1 FY27Jul 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$1.36M | −$1.04M | −$1.14M | −$2.70M | −$998.1K | −$2.20M | −$2.87M | −$3.03M |
| Net income | −$1.36M | −$1.04M | −$1.14M | −$2.70M | −$1.00M | −$2.20M | −$2.87M | −$3.03M |
| EPS (diluted) | −$3.61 | −$1.75 | $5.46 | −$1.28 | −$0.30 | −$0.58 | −$0.47 | −$0.68 |
| Balance sheet | ||||||||
| Cash and equivalents | $4.09M | $3.36M | $3.95M | $5.62M | $4.45M | $2.71M | $710.7K | $7.59M |
| Total assets | $5.01M | $4.18M | $4.60M | $6.33M | $5.09M | $4.04M | $2.08M | $8.54M |
| Total liabilities | $1.25M | $725.9K | $634.8K | $983.3K | $717.5K | $1.86M | $1.35M | $2.74M |
| Shareholders' equity | $3.75M | $3.45M | $3.97M | $5.34M | $4.37M | $2.20M | $733.2K | $5.80M |
| Cash flow | ||||||||
| Operating cash flow | −$3.40M | −$1.42M | −$688.7K | −$2.36M | −$1.17M | −$1.74M | −$2.80M | −$1.14M |
From Alzamend Neuro's 10-K and 10-Q filings with the SEC; its fiscal year ends in April. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Alzamend Neuro in our feed yet.